Patents by Inventor Naoto Fujie
Naoto Fujie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10407408Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.Type: GrantFiled: July 8, 2016Date of Patent: September 10, 2019Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Seigo Ishibuchi, Kunio Saruta, Maiko Hamada, Nobuatsu Matoba, Tetsuji Matsudaira, Maki Seki, Akiko Tarao, Takashi Honjo, Shingo Ogata, Atsushi Kawata, Kenji Morokuma, Naoto Fujie, Yukio Aoyama
-
Publication number: 20190077787Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.Type: ApplicationFiled: July 8, 2016Publication date: March 14, 2019Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Seigo ISHIBUCHI, Kunio SARUTA, Maiko HAMADA, Nobuatsu MATOBA, Tetsuji MATSUDAIRA, Maki SEKI, Akiko TARAO, Takashi HONJO, Shingo OGATA, Atsushi KAWATA, Kenji MOROKUMA, Naoto FUJIE, Yukio AOYAMA
-
Patent number: 9527859Abstract: The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): wherein each symbol has the same meaning as defined in the description, or a pharmacologically acceptable salt thereof.Type: GrantFiled: April 12, 2013Date of Patent: December 27, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masayuki Watanabe, Hiroyuki Furukawa, Maiko Hamada, Naoto Fujie, Hiroyuki Ushio, Tooru Takashima
-
Patent number: 9150555Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.Type: GrantFiled: October 13, 2011Date of Patent: October 6, 2015Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Hiroyuki Ushio, Maiko Hamada, Masayuki Watanabe, Atsushi Numata, Naoto Fujie, Tooru Takashima, Hiroyuki Furukawa, Junki Ando
-
Publication number: 20150065715Abstract: The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): wherein each symbol has the same meaning as defined in the description, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: April 12, 2013Publication date: March 5, 2015Applicant: Mitsubishi Tanabe Pharma CorporationInventors: Masayuki Watanabe, Hiroyuki Furukawa, Maiko Hamada, Naoto Fujie, Hiroyuki Ushio, Tooru Takashima
-
Publication number: 20130211075Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.Type: ApplicationFiled: October 13, 2011Publication date: August 15, 2013Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroyuki Ushio, Maiko Hamada, Masayuki Watanabe, Atsushi Numata, Naoto Fujie, Tooru Takashima, Hiroyuki Furukawa, Junki Ando
-
Patent number: 8044042Abstract: A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.Type: GrantFiled: May 30, 2006Date of Patent: October 25, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata
-
Publication number: 20100152261Abstract: A nitrogen-containing heterocyclic derivative represented by the following general formula (I), or a hydrate or solvate thereof, which has a selective antagonistic action on the muscarinic M3 receptor and causes reduced cardiac side effect and thus is safe, and has superior pharmacological efficacy and prolonged action even by inhalation administration, and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 25, 2006Publication date: June 17, 2010Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideyuki Aizawa, Makoto Seki, Jun-ichi Endoh, Minoru Tanaka, Naoto Fujie, Osamu Sakuma, Takao Kamahori
-
Publication number: 20100041643Abstract: [Solving means] A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. [Effect]Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.Type: ApplicationFiled: May 30, 2006Publication date: February 18, 2010Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata